X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (709) 709
Book Review (61) 61
Publication (46) 46
Conference Proceeding (3) 3
Book Chapter (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (685) 685
atorvastatin calcium (574) 574
humans (549) 549
male (422) 422
atorvastatin (343) 343
pharmacology & pharmacy (319) 319
female (308) 308
middle aged (241) 241
heptanoic acids - pharmacokinetics (239) 239
heptanoic acids - pharmacology (234) 234
pyrroles - pharmacokinetics (220) 220
statins (218) 218
pyrroles - pharmacology (214) 214
animals (209) 209
heptanoic acids - therapeutic use (206) 206
heptanoic acids - administration & dosage (205) 205
pyrroles - therapeutic use (199) 199
adult (198) 198
pyrroles - administration & dosage (197) 197
aged (164) 164
simvastatin (148) 148
drug interactions (142) 142
pharmacokinetics (133) 133
heptanoic acids - adverse effects (131) 131
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (131) 131
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (128) 128
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (127) 127
pyrroles - adverse effects (127) 127
cholesterol (116) 116
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (111) 111
dose-response relationship, drug (102) 102
rats (98) 98
pravastatin (96) 96
treatment outcome (88) 88
heptanoic acids - blood (86) 86
hypercholesterolemia (85) 85
hypercholesterolemia - drug therapy (84) 84
cholesterol, ldl - blood (83) 83
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (83) 83
pyrroles - blood (80) 80
anticholesteremic agents - therapeutic use (76) 76
antilipemic agents (75) 75
coa reductase inhibitors (73) 73
abridged index medicus (72) 72
cardiac & cardiovascular systems (71) 71
hmg-coa reductase (71) 71
lipids (71) 71
drug therapy (70) 70
area under curve (69) 69
drug therapy, combination (69) 69
mice (63) 63
rosuvastatin calcium (62) 62
research (61) 61
safety (60) 60
anticholesteremic agents - pharmacokinetics (59) 59
anticholesteremic agents - pharmacology (59) 59
metabolism (58) 58
analysis (57) 57
cholesterol - blood (57) 57
p-glycoprotein (54) 54
administration, oral (52) 52
cross-over studies (52) 52
heptanoic acids - metabolism (52) 52
in-vitro (52) 52
anticholesteremic agents - administration & dosage (51) 51
statin (51) 51
pyrroles - metabolism (50) 50
therapy (50) 50
atherosclerosis (48) 48
time factors (48) 48
adolescent (47) 47
heptanoic acids - chemistry (47) 47
drug-interactions (46) 46
rosuvastatin (46) 46
simvastatin - therapeutic use (46) 46
pharmacology/toxicology (45) 45
peripheral vascular disease (44) 44
pyrroles - chemistry (44) 44
young adult (44) 44
anticholesteremic agents - adverse effects (43) 43
double-blind method (43) 43
medicine & public health (43) 43
rats, sprague-dawley (42) 42
coronary-heart-disease (41) 41
metabolites (41) 41
risk factors (41) 41
simvastatin - administration & dosage (41) 41
simvastatin - pharmacology (41) 41
lovastatin (40) 40
prospective studies (40) 40
rhabdomyolysis (40) 40
disease (39) 39
toxicology (39) 39
efficacy (37) 37
biochemistry & molecular biology (36) 36
cholesterol, hdl - blood (36) 36
dyslipidemias - drug therapy (36) 36
hydroxymethylglutaryl-coa reductase inhibitors - blood (36) 36
lipids - blood (36) 36
triglycerides - blood (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (698) 698
Russian (5) 5
Chinese (2) 2
French (2) 2
Dutch (1) 1
German (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 197 - 203
The ABCG2 c.421C>A single‐nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic... 
BCRP GENE POLYMORPHISMS | ACID | HUMAN PLASMA | SLCO1B1 POLYMORPHISM | LACTONE FORMS | TRANSPORTER ABCG2 | PHARMACOLOGY & PHARMACY | INDUCED MYOPATHY | CANCER RESISTANCE PROTEIN | SINGLE NUCLEOTIDE POLYMORPHISMS | P-GLYCOPROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrroles - urine | Area Under Curve | Drug Resistance, Multiple | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | ATP-Binding Cassette Transporters - genetics | Sulfonamides - urine | Pyrroles - administration & dosage | Fluorobenzenes - urine | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Heptanoic Acids - urine | Finland | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Pyrimidines - urine | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 17, pp. 1609 - 1616
Objectives We sought to identify single nucleotide polymorphisms associated with mild statin-induced side effects. Background Statin-induced side effects can... 
Cardiovascular | Internal Medicine | clinical trial | hydroxymethylglutaryl-CoA reductase inhibitors | adverse events | single nucleotide polymorphisms | myopathy | pharmacogenetics | TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | ACID | SAFETY | SLCO1B1 POLYMORPHISM | INDUCED MYOPATHY | ATORVASTATIN | PHARMACOKINETICS | DISEASE | PRAVASTATIN | LACTONE | Haplotypes | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Male | Heptanoic Acids - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pravastatin - adverse effects | Pyrroles - adverse effects | Female | Muscular Diseases - chemically induced | Hypolipidemic Agents - adverse effects | Creatine Kinase - blood | Simvastatin - pharmacokinetics | Muscular Diseases - blood | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Aged | Polymorphism, Single Nucleotide | Hypolipidemic Agents - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Enzymes | Hypotheses | Acids | Mortality | Cardiovascular disease | Muscle pain | Drug therapy | Statins | Cholesterol | Index Medicus | Abridged Index Medicus | muscular diseases | hydroxymethylglutaryl-CoA Reductase Inhibitors
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 12/2007, Volume 82, Issue 6, pp. 726 - 733
Thirty‐two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1... 
COA REDUCTASE INHIBITOR | ANION TRANSPORTING POLYPEPTIDE | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | HEALTHY-VOLUNTEERS | INDUCED MYOPATHY | OATP-C SLC21A6 | SINGLE NUCLEOTIDE POLYMORPHISMS | CLINICAL-RELEVANCE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Prospective Studies | Pyrroles - pharmacokinetics | Area Under Curve | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Reference Values | Fluorobenzenes - administration & dosage | Organic Anion Transporters - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Organic Anion Transporters - genetics | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | European Continental Ancestry Group - genetics | Administration, Oral | Pyrimidines - administration & dosage | Liver - metabolism | Rosuvastatin Calcium | Genotype | Pyrroles - blood | Sulfonamides - pharmacokinetics | Polymorphism, Genetic | Atorvastatin Calcium | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 02/2007, Volume 81, Issue 2, pp. 194 - 204
The inhibition of hepatic uptake transporters, such as OATP1B1, on the pharmacokinetics of atorvastatin is unknown. Here, we investigate the effect of a model... 
ORGANIC ANION TRANSPORTER | COA REDUCTASE INHIBITOR | IN-VITRO | MAJOR DETERMINANT | MEDIATED HEPATIC-UPTAKE | PHARMACOLOGY & PHARMACY | HUMAN LIVER | CLINICAL PHARMACOKINETICS | SINGLE NUCLEOTIDE POLYMORPHISMS | DRUG-DRUG INTERACTION | P-GLYCOPROTEIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - metabolism | Rifampin - pharmacokinetics | Liver - enzymology | Pyrroles - pharmacokinetics | Tablets | Area Under Curve | Bile - chemistry | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Substrate Specificity | Bile - metabolism | Male | Enzyme Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Transfection | Enzyme Inhibitors - pharmacokinetics | Liver - drug effects | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Biological Transport - drug effects | Rifampin - administration & dosage | Binding, Competitive | Cell Line | Pyrroles - metabolism | Organic Anion Transporters - antagonists & inhibitors | Enzyme Inhibitors - metabolism | Administration, Oral | Cross-Over Studies | Organic Anion Transporters - physiology | Adolescent | Atorvastatin | Bile - drug effects | Liver-Specific Organic Anion Transporter 1 | Infusions, Intravenous | Rifampin - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2012, Volume 55, Issue 10, pp. 4740 - 4763
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Circulation Research, ISSN 0009-7330, 02/2010, Volume 106, Issue 2, pp. 297 - 306
RATIONALE:The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, are important drugs used in the treatment and prevention of... 
Statins | Drug transporters | Myopathy | CARDIAC & CARDIOVASCULAR SYSTEMS | myopathy | EUROPEAN-AMERICANS | HEPATIC-UPTAKE | INDUCED MYOPATHY | P-GLYCOPROTEIN | drug transporters | LIPID-LOWERING DRUGS | statins | ORGANIC-ANIONS | PERIPHERAL VASCULAR DISEASE | COA-REDUCTASE INHIBITORS | RESISTANCE-ASSOCIATED PROTEIN-2 | HEALTHY-VOLUNTEERS | MULTIDRUG-RESISTANCE | HEMATOLOGY | Immunohistochemistry | Fluorobenzenes - pharmacokinetics | Heptanoic Acids - metabolism | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Immunoblotting | Muscle, Skeletal - metabolism | Gene Expression Profiling | Muscle, Skeletal - cytology | Organic Anion Transporters - metabolism | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Myoblasts - metabolism | Organic Anion Transporters - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Myoblasts - cytology | Multidrug Resistance-Associated Proteins - genetics | Heptanoic Acids - pharmacology | Cell Survival - drug effects | Fluorobenzenes - metabolism | Pyrroles - metabolism | Cells, Cultured | Rosuvastatin Calcium | Pyrimidines - pharmacology | Reverse Transcriptase Polymerase Chain Reaction | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Atorvastatin Calcium | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - metabolism | Pyrimidines - pharmacokinetics | HeLa Cells | Multidrug Resistance-Associated Proteins - metabolism | Index Medicus
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood | Index Medicus
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2013, Volume 69, Issue 3, pp. 477 - 487
Interactions between ticagrelor and atorvastatin or simvastatin were investigated in two-way crossover studies.Both studies were open-label for statin; the... 
Co-administration | AZD6140 | Biomedicine | Simvastatin | Atorvastatin | Pharmacology/Toxicology | Ticagrelor | Pharmacokinetics | COA REDUCTASE INHIBITORS | SLCO1B1 POLYMORPHISM | ACUTE CORONARY SYNDROMES | CLINICAL PHARMACOKINETICS | STATINS | RECEPTOR ANTAGONIST | SERUM CONCENTRATIONS | TASK-FORCE | PHARMACOLOGY & PHARMACY | P2Y RECEPTOR | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Adenosine - pharmacokinetics | Purinergic P2Y Receptor Antagonists - administration & dosage | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Half-Life | Male | Metabolic Clearance Rate | Heptanoic Acids - adverse effects | Simvastatin - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Pyrroles - administration & dosage | Adenosine - adverse effects | Biotransformation | Platelet Aggregation Inhibitors - administration & dosage | Heptanoic Acids - administration & dosage | Pyrroles - adverse effects | Adult | Female | Platelet Aggregation Inhibitors - pharmacokinetics | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Simvastatin - administration & dosage | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Linear Models | Pyrroles - blood | Simvastatin - pharmacokinetics | Adenosine - administration & dosage | Cross-Over Studies | Atorvastatin Calcium | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Adenosine - analogs & derivatives | Least-Squares Analysis | Heptanoic Acids - blood | Dosage and administration | Metabolites | Drug interactions | Antilipemic agents | Drug therapy | Pharmacology | Kinetics | Index Medicus
Journal Article